When Scientists Pick a Fight with the Law
By Osagie K. Obasogie,
Science Progress
| 04. 07. 2010
Since the times of Galileo and as recently as climate change researchers’ battles with the Bush administration, scientists have defended themselves against what they perceive to be undue intrusion into their research by government and other authorities. But rarely have scientists gone out of their way to start a fight with Johnny Law.
This dynamic seems to be changing in the field of DNA forensics. Two dozen scientists (along with several other scholars and practitioners) recently published an open letter in the prestigious journal Science that called out the Federal Bureau of Investigation for stonewalling research access to the federal DNA database. This database houses almost eight million DNA profiles used to identify unknown offenders who leave biological materials at crime scenes.
Why are scientists poking this bear with a stick? DNA evidence is particularly compelling because the chance that any two samples match coincidentally is slim to none; experts often express the probability as only one in several million. This is also why DNA is useful in exonerating individuals who are wrongly accused; testing can show that unknown samples...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...